Early deaths resulting from immunotherapy in the treatment of melanoma
Background: Immunotherapy is widely applied in the management of high-risk and advanced melanoma, resulting in significant advancements in clinical outcomes. Nonetheless, immune checkpoint inhibitors are frequently linked to diverse immune-related adverse events (irAEs) and, in rare instances, may result in fatal outcomes.
Authors
- Paweł Teterycz (ORCID: https://orcid.org/0000-0001-7304-714X)
- A. Mariuk-Jarema
- H. Koseła-Paterczyk
- Sylwia Kopeć
- P. Rutkowski
- S. Rynkun
Institutions
- National Institute of Oncology (HU)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
Publication Details
- Journal
- EJC Skin Cancer
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.ejcskn.2025.100543
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00